Deployment o the Multidisciplinary Prospective Cohort Imminent

  • STATUS
    Recruiting
  • End date
    Jul 24, 2031
  • participants needed
    2000
  • sponsor
    University Hospital, Lille
Updated on 24 May 2021
disease or disorder

Summary

Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.

Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment.

These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.

Details
Condition Eczema, Psoriasis, Multiple Sclerosis, Angioneurotic Edema, Urticaria, Vascular Diseases, CONNECTIVE TISSUE DISEASE, PSORIATIC ARTHRITIS, Systemic sclerosis, Lupus Vulgaris, Discoid lupus erythematosus, Dermatosis, SYSTEMIC LUPUS ERYTHEMATOSUS, ATOPIC DERMATITIS, Dermatitis, Arthritis, Severe Asthma, Chronic Inflammatory Disease, Chronic Inflammatory Disorder, Lupus, multiple sclerosis (ms), angioedema, quincke's edema, progressive systemic sclerosis, Behçet Disease
Treatment Biobanking with genetic analysis, SF-12 questionnaire
Clinical Study IdentifierNCT04334031
SponsorUniversity Hospital, Lille
Last Modified on24 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology)
Social insured
Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures

Exclusion Criteria

Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system
Pregnant or breastfeeding woman
Persons deprived of liberty
Protected minors or adults
Persons who have refused or are incapable of giving informed consent
Persons in Emergency Situations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note